OssDsign appoints ABG Sundal Collier as Liquidity Provider
OssDsign AB (publ) (“OssDsign”) has agreed with ABG Sundal Collier ASA (“ABGSC”) that ABGSC shall act as liquidity provider for OssDsign’s share on Nasdaq First North. The purpose is to improve the liquidity of the share and the assignment commences on June 8th 2020.
A liquidity provider’s aim is to improve the liquidity of a share and reduce the spread between the bidding and asking price. ABGSC will fulfill its assignment as liquidity provider to ensure the possibility of trading in OssDsign’s share every day by continuously placing trading records on each purchase and sales page in the order book. A liquidity provider aims to create a more accurate pricing of a company's share, which in turn gives a more accurate valuation of the company and allows for an improved trading volume in the share.
The assignment begins on June 8, 2020, and it is carried out within the framework of Nasdaq Stockholm AB’s regulations on liquidity providers. This means that the liquidity provider will quote bid and asking prices corresponding to a volume of at least SEK 15,000 with a maximum spread of 4 % between bid and asking price.
For further information, please contact:
Anders Lundqvist, CEO, OssDsign AB
Tel: +46 73 206 98 08, email: al@ossdsign.com
Certified Adviser
The Company’s Certified Adviser is Erik Penser Bank AB. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.
About OssDsign
OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.
This information is information that OssDsign AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 09:00 CET on June 5th, 2020